Novo Nordisk's CagriSema leads to significant weight loss in late-stage trial

From Nasdaq: 2025-06-22 13:11:00

Novo Nordisk’s Phase 3 REDEFINE 1 trial showed that CagriSema led to a 22.7% weight loss at 68 weeks for adherent patients, compared to 2.3% in the placebo group. Overall, the CagriSema group achieved a 20.4% weight loss versus 3.0% with placebo. A secondary analysis revealed that 50.7% of participants treated with CagriSema reached non-obesity levels, while only 10.2% in the placebo group achieved the same. CagriSema combines semaglutide and cagrilintide. The results were published in the New England Journal of Medicine and presented at the American Diabetes Association’s Scientific Sessions. For more health news, visit rttnews.com.



Read more at Nasdaq: Novo Nordisk’s CagriSema Shows Major Weight Loss In Late-Stage Trial